This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Investing in your 20s can set the foundation for a secure retirement. Discover the best options to maximize your growth.
17,680 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Oil and currency markets tremble as new Iran-related tensions top the global agenda. Asia, with its export-led growth...
A patient investor could see a multi-year rebound in a little-known robotics stock. Learn the growth drivers, how to ...
Explore Viemed's 2026 earnings outlook with a practical, numbers-driven view. Learn the key drivers, risks, and how t...
As Zymeworks gears up for 2026 earnings, investors should focus on cash runway, pipeline milestones, and collaboratio...
Oil sits around $107.70 a barrel on May 11, 2026, supported by producer discipline and steady demand. The move could ...
Geopolitical shocks can destabilize oil markets. This guide explains why midstream oil stocks often prove resilient d...
A standard checking account with near-zero yields can quietly erode a $30,000 emergency fund over ten years. By movin...
UiPath faced a cautious session as its Korea cloud launch tests regional demand. This article breaks down what happen...
When a CFO sells shares after exercising options, investors want the real story. This article explains what ambiq mic...
If SpaceX ever files for an IPO, the prospectus would reveal the core drivers, the risks, and the questions investors...
Greg Abel is stepping into big shoes as Warren Buffett's successor. This article breaks down three bold purchases he ...